X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (7) 7
humans (6) 6
index medicus (6) 6
male (6) 6
chemotherapy (5) 5
aged (4) 4
cetuximab (4) 4
female (4) 4
gemcitabine (4) 4
middle aged (4) 4
patients (4) 4
survival (4) 4
aged, 80 and over (3) 3
analysis (3) 3
animals (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
body weight (3) 3
cancer (3) 3
cancer therapies (3) 3
colorectal neoplasms - drug therapy (3) 3
colorectal neoplasms - genetics (3) 3
medical prognosis (3) 3
metastasis (3) 3
neoplasm metastasis (3) 3
nutrition & dietetics (3) 3
pancreatic cancer (3) 3
proteins (3) 3
rats (3) 3
therapy (3) 3
abridged index medicus (2) 2
adenocarcinoma (2) 2
adipocytes (2) 2
adipose tissue, white - drug effects (2) 2
adult (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antigens (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
bioindicators (2) 2
biomarkers (2) 2
camptothecin - administration & dosage (2) 2
camptothecin - analogs & derivatives (2) 2
cells (2) 2
clinical trials (2) 2
colorectal cancer (2) 2
colorectal neoplasms - pathology (2) 2
egfr (2) 2
expression (2) 2
fatty acids (2) 2
fluorouracil - administration & dosage (2) 2
folfiri (2) 2
growth factors (2) 2
growth-factor-receptor (2) 2
insulin-resistance (2) 2
irinotecan (2) 2
leucovorin - administration & dosage (2) 2
ly2157299 monohydrate (2) 2
lymphocytes (2) 2
medical colleges (2) 2
metastases (2) 2
mutation (2) 2
obesity (2) 2
organ size (2) 2
oxaliplatin (2) 2
phase-ii trial (2) 2
randomization (2) 2
receptor, epidermal growth factor - antagonists & inhibitors (2) 2
research (2) 2
studies (2) 2
toxicity (2) 2
transforming growth factor-b (2) 2
treatment outcome (2) 2
triglycerides - blood (2) 2
tumors (2) 2
1st-line treatment (1) 1
2nd-line chemotherapy (1) 1
3t3-l1 adipocytes (1) 1
5-fluorouracil (1) 1
acetyl-coa carboxylase - metabolism (1) 1
acids (1) 1
activation (1) 1
adipocytes - drug effects (1) 1
adipocytes - metabolism (1) 1
adipose tissue - pathology (1) 1
adipose tissue, brown - drug effects (1) 1
adipose tissue, brown - physiology (1) 1
adipose tissue, white - metabolism (1) 1
adipose tissue, white - physiology (1) 1
adipose tissues (1) 1
adult humans (1) 1
advanced solid tumors (1) 1
amino acid transport systems, neutral - genetics (1) 1
amino acid transport systems, neutral - metabolism (1) 1
amphiregulin (1) 1
anti-pd-1 antibody (1) 1
antibodies (1) 1
antibodies, monoclonal - pharmacology (1) 1
antibodies, monoclonal, humanized (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antibody targeted therapy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 8, pp. 753 - 762
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10018, pp. 545 - 557
Summary Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated... 
Internal Medicine | PLUS GEMCITABINE | SURVIVAL | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | ADENOCARCINOMA | 2ND-LINE CHEMOTHERAPY | OXALIPLATIN | PEP02 | DOCETAXEL | CARCINOMA | FOLFIRI | Leucovorin - administration & dosage | Humans | Middle Aged | Male | Fatigue - chemically induced | Diarrhea - chemically induced | Pancreatic Neoplasms - drug therapy | Neoplasm Metastasis | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Camptothecin - administration & dosage | Carcinoma, Pancreatic Ductal - mortality | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Neutropenia - chemically induced | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Pancreatic Ductal - drug therapy | Irinotecan | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Liposomes | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Pancreatic cancer | Leucovorin | Product development | Research institutes | Metastasis | Antineoplastic agents | Analysis | Antigens | Chemotherapy | Medical prognosis | Clinical trials | Drug dosages | Cancer therapies | Tumors | Adenocarcinoma | Slopes | Therapy | Gemcitabine | Toxicity | Metastases | Nanoparticles | Randomization | Motivation | Vomiting | Safety management | Toxic diseases | Neutropenia | Folinic acid | Lymphatic system | Medical treatment | Diarrhea | FDA approval | Survival | Patients | Acids | Equivalence | Interactive systems
Journal Article
Journal Article
Obesity, ISSN 1930-7381, 01/2017, Volume 25, Issue 1, pp. 111 - 121
Objective: To analyze whether a combination of quercetin (Q) and resveratrol (RSV) would induce a white adipose tissue (WAT) browning effect. Methods:... 
ENERGY | HOMEOSTASIS | ACTIVATION | NUTRITION & DIETETICS | C57BL/6J MICE | ADIPOCYTES | HIGH-FAT DIET | INSULIN-RESISTANCE | GLUCOSE | ENDOCRINOLOGY & METABOLISM | ADULT HUMANS | EXPRESSION | Body Weight | Bone Morphogenetic Protein 4 - genetics | Adipocytes - drug effects | Fatty Acid-Binding Proteins - metabolism | Stilbenes - pharmacology | RNA, Messenger - metabolism | Bone Morphogenetic Protein 4 - metabolism | Cyclooxygenase 2 - genetics | Adipose Tissue, White - physiology | Apoptosis Regulatory Proteins - genetics | Uncoupling Protein 1 - genetics | Uncoupling Protein 1 - metabolism | RNA, Messenger - genetics | Adipose Tissue, Brown - physiology | Rats | Amino Acid Transport Systems, Neutral - metabolism | Lipase - metabolism | Fatty Acid-Binding Proteins - genetics | Symporters - metabolism | Amino Acid Transport Systems, Neutral - genetics | Apoptosis Regulatory Proteins - metabolism | Animals | Diet | Quercetin - pharmacology | Adipocytes - metabolism | Symporters - genetics | Cyclooxygenase 2 - metabolism | Adipose Tissue, Brown - drug effects | Adipose Tissue, White - drug effects | Lipase - genetics | Obesity | Homeostasis | Mitochondrial DNA | Adipocytes | Gene expression | Fatty acids | Proteins | Studies | Thermogenesis | Rodents | Morphology | Polyphenols | Protein expression | Oxidation | Deoxyribonucleic acid--DNA
Journal Article
British Journal of Cancer, ISSN 0007-0920, 06/2015, Volume 112, Issue 12, pp. 1874 - 1881
Background: The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic... 
KRAS-mutated metastatic colorectal cancer | MEK inhibitor | pimasertib | combination therapy second-line treatment | FOLFIRI | 1ST-LINE TREATMENT | ADVANCED SOLID TUMORS | KINASE INHIBITORS | ORAL MEK1/2 INHIBITOR | FLUOROURACIL | CHEMOTHERAPY | TRIAL | CETUXIMAB | TARGETED THERAPIES | ONCOLOGY | MSC1936369B/AS703026 | Niacinamide - analogs & derivatives | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Male | Neoplasm Metastasis | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Niacinamide - pharmacokinetics | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Camptothecin - pharmacokinetics | Colorectal Neoplasms - enzymology | Proto-Oncogene Proteins - genetics | Treatment Outcome | Leucovorin - pharmacokinetics | Niacinamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | Colorectal Neoplasms - pathology | Fluorouracil - pharmacokinetics | Genes, ras | Index Medicus | second-line treatment | combination therapy | Clinical Study
Journal Article
Journal Article
Future Oncology, ISSN 1479-6694, 06/2019, Volume 15, Issue 16, pp. 1811 - 1822
Advanced, unresectable hepatocellular carcinoma (HCC) has a poor prognosis with median life expectancy of approximately 1 year. Overexpression of PD-L1 in... 
HCC | tislelizumab | PD-1 | hepatocellular carcinoma | MULTICENTER | PLACEBO | LANDSCAPE | THERAPY | ANTI-PD-1 ANTIBODY | ONCOLOGY | POSTOPERATIVE RECURRENCE | REGORAFENIB | DOUBLE-BLIND | BRIVANIB | T-CELLS
Journal Article
Gut, ISSN 0017-5749, 07/2014, Volume 64, Issue 6, pp. 921 - 928
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.